Sotrovimab早期治疗Covid-19
COMET-ICE为正在进行中的多中心、双盲、3期试验,纳入非住院、有症状≤5天、至少一项疾病进展危险因素的Covid-19患者,按1:1随机接受单次sotrovimab 500 mg输注或安慰剂。预设中期分析意向治疗人群583例(sotrovimab 291例、安慰剂292例),主要终点29天内任何原因住院>24小时或死亡:sotrovimab组3例(1%)vs安慰剂组21例(7%),相对风险降低85%(97.24%CI 44-96,P=0.002)。安全性人群868例,不良事件17% vs 19%,严重不良事件2% vs 6%。结论:高风险轻中度Covid-19患者中sotrovimab降低疾病进展风险,未发现安全信号。
要点
- 适用:非住院、有症状≤5天、至少一项疾病进展危险因素的轻中度Covid-19患者。
- 单次静脉输注sotrovimab 500 mg,安慰剂对照,1:1随机。
- 主要终点29天内住院>24小时或死亡:1%(3/291)vs 7%(21/292),相对风险降低85%(97.24%CI 44-96,P=0.002)。
- 安慰剂组5例入住ICU、1例第29天前死亡;sotrovimab组原文未提及ICU入住或死亡例数。
- 安全性人群868例:不良事件17% vs 19%,严重不良事件2% vs 6%。
适用人群与场景
- 非住院的Covid-19患者,有症状≤5天,且至少一项疾病进展危险因素;按1:1随机接受单次sotrovimab 500 mg输注或安慰剂。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 对符合条件的高风险非住院轻中度Covid-19患者,在症状出现≤5天内单次静脉输注sotrovimab 500 mg(原文未提及输注途径细节、频次或疗程,仅写single infusion)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:正在进行中的多中心、双盲、3期随机对照试验(COMET-ICE,NCT04545060),预设中期分析。
- 样本量与中心数:意向治疗人群583例(sotrovimab 291例、安慰剂292例);安全性人群868例(sotrovimab 430例、安慰剂438例);原文未提及中心数。
- 人群:非住院、有症状≤5天、至少一项疾病进展危险因素的Covid-19患者。
- 干预与对照:单次输注sotrovimab 500 mg vs 安慰剂,1:1随机。
- 主要终点:29天内任何原因住院>24小时或死亡,sotrovimab组3例(1%)vs安慰剂组21例(7%),相对风险降低85%(97.24%CI 44-96,P=0.002)。
- 关键次要终点:原文未提及。
- 不良事件:sotrovimab组17% vs安慰剂组19%;严重不良事件2% vs 6%。
- 安慰剂组5例入住ICU(含1例第29天前死亡);sotrovimab组ICU入住或死亡例数原文未提及。
证据类型、等级与局限
- 证据类型:多中心、双盲、3期随机对照试验的预设中期分析。
- 证据等级或推荐强度:原文未提及。
- 局限:为正在进行试验的中期分析;原文未提及其他局限。
对床旁实践的改变
- 对非住院、有症状≤5天、至少一项疾病进展危险因素的轻中度Covid-19患者,可考虑在病程早期单次输注sotrovimab 500 mg以降低29天内住院或死亡风险。
- 适用人群为原文纳入的非住院高风险患者;不适用于住院患者(原文未纳入)及无疾病进展危险因素者(原文未纳入)。
指南或共识出处
- COMET-ICE试验(ClinicalTrials.gov NCT04545060),由Vir Biotechnology和GlaxoSmithKline资助;发表于N Engl J Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization.
RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively).
CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).
参考来源
- Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021. PMID: 34706189. doi:10.1056/NEJMoa2107934
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。